Korean J Urol.  2008 Nov;49(11):1007-1012. 10.4111/kju.2008.49.11.1007.

The Effectiveness of Transurethral Resection of the Prostate Combined with High Power Potassium-titanyl-phosphate(KTP) Laser Vaporization for Patients with a Prostate Volume Greater than 45cc

• Yang SW
• Yu JH
• Sung LH
• Chung JY
• Noh CH

• KMID: 1328173
• DOI: http://doi.org/10.4111/kju.2008.49.11.1007

Abstract

PURPOSE: We compared the effectiveness of transurethral resection of the prostate(TURP) with the effectiveness of high power potassium-titanyl-phosphate(KTP) laser vaporization combined with TURP in patients with a prostate volume over 45cc.
MATERIALS AND METHODS
Between March 2004 and March 2007, we analyzed all the patients with a prostate volume over 45cc and who underwent TURP or KTP laser vaporization combined with TURP for treating symptomatic benign prostatic hyperplasia(BPH). The patients were divided into two groups(Group I: TURP: n=53, Group II: KTP laser vaporization combined with TURP: n=54). The initial evaluation included a digital rectal examination, urinalysis, determining the hemoglobin, electrolyte and prostate-specific antigen(PSA) levels, the International Prostate Symptom Score(IPSS), the quality of life(QoL), the maximum urine flow rate (Qmax), the postvoiding residual urine(PVR), transrectal ultrasonography (TRUS) and urodynamic study. The postoperative hemoglobin and electrolyte levels were checked promptly, and the total operation time, the foley indwelling period and the number of hospital days were recorded afterwards. The IPSS, QoL, Qmax, and PVR were evaluated at 1 and 3 months postoperatively.
RESULTS
The baseline characteristics and postoperative outcomes of the two groups were similar. The total blood loss during operation was significantly lower in Group II(p=0.02).
CONCLUSIONS
KTP laser vaporization combined with TURP resulted in less blood loss than TURP and it provided a good operation field in those patients who have over 45cc of prostate. Thus, KTP laser vaporization combined with TURP is safer than performing only TURP.

Keyword

KTP laser; Transurethral resection of prostate; Safety

Reference

1. Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE. Transurethral resection of the prostate among medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology. 1994. 44:692–698.

2. Gu F. Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China. Chin Med J (Engl). 2000. 113:299–302.

3. National Health Insurance Yearly Book. 20th, 21th, 22th, 23th ed. National Health Insurance Cooperation.

4. AUA Practice Guidelines Committee. AUA guideline in management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. AUA Practice Guidelines Committee. J Urol. 2003. 170:530–547.

5. Perrin P, Barnes R, Hadley H, Bergman RT. Forty years of transurethral prostatic resections. J Urol. 1976. 116:757–758.

6. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989. 141:243–247.

7. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectmy in the 1990s. J Urol. 1999. 162:1307–1310.

8. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of randomized trial. J Endourol. 2006. 20:580–585.

9. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70ml: a short-term prospective randomized trial. Urology. 2008. 71:247–251.

10. Alschibaja M, May F, Treiber U, Paul R, Hartung R. Transurethral resection for benign prostatic hyperplasia. Current developments. Urologe A. 2005. 44:499–504.

11. Singh H, Desai MR, Shrivastav P, Vani K. Bipolar versus monopolar transurethral resection of prostate: randomized controlled study. J Endourol. 2005. 19:333–338.

12. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology. 1998. 51:23–31.

13. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol. 2005. 174:1344–1348.

14. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. High-power potassium-titanyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostatic hyperplasia in men with large prostates. Urology. 2004. 64:1155–1159.

15. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 1999. 53:473–480.

16. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology. 1998. 51:46–49.

17. Verger-Kuhnke AB, Reuter M, Epple W, Ungemach G, Beccaría ML. Combined treatment of prostate adenoma with the 80 Watt KTP-laser and low-pressure transurethral resection. Urol Esp. 2006. 30:394–401.